We believe that the development of a selective inhibitor of ALDH1A3, could lead to the investigation of a possible co-administration with the Temozolomide [36], the only specific drug for glioblastoma treatment, to increase the final effect of the already existing molecule, reducing the side effects. The gene discussed is ALDH1A3; the disease is glioblastoma.